Repligen Co. (NASDAQ:RGEN) Shares Purchased by Atria Investments Inc

Atria Investments Inc raised its holdings in Repligen Co. (NASDAQ:RGEN) by 67.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,202 shares of the biotechnology company’s stock after purchasing an additional 1,295 shares during the period. Atria Investments Inc’s holdings in Repligen were worth $477,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Andra AP fonden purchased a new stake in Repligen during the 2nd quarter worth about $25,000. International Assets Investment Management LLC acquired a new position in shares of Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. lifted its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the period. Lazard Asset Management LLC boosted its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on RGEN. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Price Performance

RGEN opened at $138.90 on Thursday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a 50 day moving average of $140.30 and a two-hundred day moving average of $143.67. The company has a market cap of $7.78 billion, a P/E ratio of -375.41, a P/E/G ratio of 3.75 and a beta of 0.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company earned $0.23 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. On average, analysts expect that Repligen Co. will post 1.52 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.